CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Monday reported a loss of $30.3 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of 36 cents per share.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.

The drug developer posted revenue of $1.4 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $9.1 million.

Seres Therapeutics shares have climbed tenfold since the beginning of the year. The stock has increased ninefold in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCRB at https://www.zacks.com/ap/MCRB

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News